C3N-02922
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 54.96783025
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.680
- ALLOGRAFT_REJECTION+0.650
- IL6_JAK_STAT3_SIGNALING+0.560
- INFLAMMATORY_RESPONSE+0.490
- E2F_TARGETS+0.410
- COMPLEMENT+0.390
- G2M_CHECKPOINT+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- IL2_STAT5_SIGNALING+0.270
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- HEDGEHOG_SIGNALING-0.390
- PROTEIN_SECRETION-0.370
- GLYCOLYSIS-0.360
- ADIPOGENESIS-0.330
- ESTROGEN_RESPONSE_LATE-0.330
- ESTROGEN_RESPONSE_EARLY-0.310
- NOTCH_SIGNALING-0.310
- FATTY_ACID_METABOLISM-0.300
- PEROXISOME-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.898 |
| 2 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.891 |
| 3 | TCGA-AR-A1AW-01A-21R-A12P-07 | — | D | 0.891 |
| 4 | TCGA-AO-A128-01A-11R-A10J-07 | — | D | 0.888 |
| 5 | SRR29022833 | — | D | 0.885 |
| 6 | TCGA-EW-A1OV-01A-11R-A144-07 | — | D | 0.870 |
| 7 | TCGA-AR-A0TT-01A-31R-A084-07 | — | D | 0.869 |
| 8 | SRR8613787 | — | D | 0.856 |
| 9 | SRR8613734 | — | D | 0.855 |
| 10 | SRR6013475 | — | cohortMD2 | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.680 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.650 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |